patient_id	feature_display	tested_subfeature	therapy_name	n_mut	n_wt	n_mut_tested	n_wt_tested	mut_ic50_median	mut_ic50_mean	mut_ic50_std	wt_ic50_median	wt_ic50_mean	wt_ic50_std	pvalue_mww	statistic
PROS12319B-SU2C-06115118	CCNE1 Amplification	CCNE1	Bortezomib	119	1704	65	691	0.008	0.022	0.052	0.007	0.026	0.148	0.077	19492.5
PROS12319B-SU2C-06115118	CCNE1 Amplification	CCNE1 Copy Number	Bortezomib	94	1729	53	703	0.009	0.026	0.057	0.007	0.026	0.147	0.028	15263.0
PROS12319B-SU2C-06115118	CCNE1 Amplification	CCNE1 Copy Number Amplification	Bortezomib	57	1766	33	723	0.008	0.02	0.045	0.007	0.026	0.145	0.229	10457.0
PROS12319B-SU2C-06115118	SLC45A3--ETV1 Fusion	SLC45A3	Sorafenib	76	1747	41	716	8.069	29.259	77.835	11.848	37.73	108.503	0.026	17713.5
PROS12319B-SU2C-06115118	SLC45A3--ETV1 Fusion	ETV1	Sorafenib	228	1595	120	637	15.092	42.003	99.024	11.058	36.38	108.54	0.043	33767.5
PROS12319B-SU2C-06115118	SLC45A3--ETV1 Fusion	SLC45A3 Fusions	Sorafenib	1	1822	1	756	467.394	467.394		11.473	36.702	105.964	0.089	6.0
PROS12319B-SU2C-06115118	SLC45A3--ETV1 Fusion	ETV1 Fusions	Sorafenib	0	1823	0	757				11.486	37.271	107.045	nan	
PROS12319B-SU2C-06115118	SLC45A3--ETV1 Fusion	SLC45A3--ETV1	Sorafenib	0	1823	0	757				11.486	37.271	107.045	nan	
